SCHEMBL4143591

SCHEMBL4143591

O=C1N=C(Nc2ccc(C(Br)C(=O)O)c(F)c2)S/C1=C\c1ccc(-c2ccc(NCc3ccccc3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
ALOX5 P09917 7/20 0.38
CISD1 Q9NZ45 1/20 0.37
HIF1A Q16665 1/20 0.35
FFAR1 O14842 4/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
ENPP2 Q13822 1/20 0.33
ELANE P08246 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143594 1.00 MAOA (0.43) MAOAMAOBALOX5CISD1HIF1A
SCHEMBL4137074 0.84 ALOX5 (0.36) ALOX5CISD1
SCHEMBL4140153 0.80 HDAC1 (0.32) ALOX5CISD1FFAR1
SCHEMBL4140156 0.80 HDAC1 (0.32) ALOX5CISD1FFAR1
SCHEMBL4128499 0.78 PTP4A3 (0.47) ALOX5CISD1
SCHEMBL4128497 0.78 PTP4A3 (0.47) ALOX5CISD1
SCHEMBL4128197 0.77 ALOX5 (0.41) ALOX5
SCHEMBL4128194 0.77 ALOX5 (0.41) ALOX5
SCHEMBL4128820 0.76 KMT2A (0.47) ALOX5CISD1
SCHEMBL4128816 0.76 KMT2A (0.47) ALOX5CISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MAOA 658/4885MAOB 202/4885ALOX5 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.